AbbVie gains on Health Canada approval for MAVIRET
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy ABBV?
AbbVie Inc's stock rose by 3.65% as it reached a 20-day high, reflecting positive investor sentiment in the health sector.
The increase is attributed to AbbVie's recent approval from Health Canada for its drug MAVIRET to treat hepatitis C, enhancing treatment options for patients and potentially expanding the company's market share in Canada. This approval allows healthcare providers to initiate treatment immediately upon diagnosis, improving patient outcomes and aligning with the growing demand for effective hepatitis treatments.
This development not only strengthens AbbVie's position in the competitive pharmaceutical market but also highlights the company's commitment to addressing critical health needs, which could lead to further growth opportunities in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 230.110
Low
223.00
Averages
252.00
High
289.00
Current: 230.110
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Shares Dip Following Phase 1 Study Results of ABBV-295
- Obesity Drug Progress: AbbVie reported in its Phase 1 study that ABBV-295 demonstrated clinically meaningful, dose-dependent weight reductions, with mean percentage changes ranging from -7.75% to -9.79% at week 12, highlighting the drug's potential despite overall market pressures.
- Market Performance Pressure: AbbVie shares fell 0.25% to $229.52 amid a broader market decline, although the stock has increased by 6.06% over the past 12 months, indicating a strong long-term trend.
- Technical Analysis Signals: The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, suggesting some short-term strength, but with an RSI of 53.14 indicating neutral territory, caution is advised for investors.
- Analyst Ratings Optimistic: Despite stock fluctuations, AbbVie holds a “Buy” rating with an average price target of $241.24, with recent positive targets set by RBC Capital and Barclays, reflecting market confidence in its future performance.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
SPYM ETF 52-Week Price Analysis
- Price Range Analysis: SPYM ETF's 52-week low is $56.6699 and high is $82.1079, with the latest trade at $78.12, indicating significant price fluctuations over the past year that can help investors assess market performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper technical insights, aiding in more informed investment decisions, although the specific 200-day moving average value is not mentioned in the article.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, providing high liquidity in the market.
- Monitoring Inflows and Outflows: Weekly monitoring of changes in ETF units focuses on notable inflows (new units created) or outflows (old units destroyed), with these dynamics potentially impacting not only the ETF itself but also the individual stocks held within it.
See More
AbbVie's ABBV-295 Shows Significant Weight Loss in Phase 1 Study
- Significant Weight Loss: AbbVie's amylin analogue ABBV-295 demonstrated an average weight loss of 7.75% to 9.79% at week 12 with weekly dosing, indicating its potential to reshape the obesity treatment landscape.
- Flexible Dosing Regimen: With bi-weekly dosing followed by monthly dosing, average weight loss ranged from 7.86% to 9.73% at week 13, showcasing the drug's effectiveness across various administration schedules, enhancing its clinical applicability.
- Good Safety Profile: ABBV-295 was well tolerated across all doses (2mg to 14mg) with no serious adverse events reported, and the most common side effects were mild gastrointestinal issues, which increases its market acceptance.
- Mechanism Advantage: As an agonist activating amylin and calcitonin receptors, ABBV-295 offers a different mechanism of action compared to dominant GLP-1 drugs, potentially introducing new competitive dynamics in the obesity treatment market.
See More
AbbVie Reports Positive Results for ABBV-295 in Phase 1 Study
- Clinical Trial Results: AbbVie announced positive topline results from the Phase 1 study of ABBV-295, indicating good safety and tolerability, particularly highlighting significant weight loss effects.
- Weight Loss Efficacy: During the 12-13 week treatment period, the ABBV-295 group showed dose-dependent weight changes ranging from -7.75% to -9.79% at week 12, compared to only -0.26% in the placebo group, underscoring ABBV-295's potential in weight management.
- Participant Demographics: The study primarily enrolled male participants (88.3%) with a body mass index (BMI) below 30 kg/m2, providing insights into the target demographic for future marketing strategies.
- Dosing and Frequency: Various doses (2-14 mg) and titration frequencies were tested, with ABBV-295 demonstrating good tolerability across all levels, laying a solid foundation for its clinical application moving forward.
See More
Subtle Success of a Neglected Dividend ETF
Dividend Stocks and Investment Considerations: Investors are often drawn to dividend stocks based on their high yields, but it's essential to consider other factors such as the company's dividend growth history and potential challenges that may affect payouts.
Diversification through ETFs: Dividend-focused exchange-traded funds (ETFs) can provide a diversified approach to investing in dividend-paying companies, helping to balance risk and enhance stability in an investment portfolio.
Performance of DGRO ETF: The DGRO ETF, which tracks U.S. companies with a history of dividend growth, has shown strong performance, returning about 13% over the past year and offering a yield of nearly 2%.
Investment Recommendations: Analysts suggest considering a range of dividend stocks, including lesser-known firms, to ensure a well-rounded investment strategy, as they may provide stability and growth potential even in fluctuating market conditions.
See More
AbbVie Shares Dip Following Phase 1 Study Results of ABBV-295
- Obesity Drug Progress: AbbVie reported in its Phase 1 study that ABBV-295 demonstrated clinically meaningful, dose-dependent weight reductions, with mean percentage changes ranging from -7.75% to -9.79% at week 12, highlighting the drug's potential despite overall market pressures.
- Market Performance Pressure: AbbVie shares fell 0.25% to $229.52 amid a broader market decline, although the stock has increased by 6.06% over the past 12 months, indicating a strong long-term trend.
- Technical Analysis Signals: The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, suggesting some short-term strength, but with an RSI of 53.14 indicating neutral territory, caution is advised for investors.
- Analyst Ratings Optimistic: Despite stock fluctuations, AbbVie holds a “Buy” rating with an average price target of $241.24, with recent positive targets set by RBC Capital and Barclays, reflecting market confidence in its future performance.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
SPYM ETF 52-Week Price Analysis
- Price Range Analysis: SPYM ETF's 52-week low is $56.6699 and high is $82.1079, with the latest trade at $78.12, indicating significant price fluctuations over the past year that can help investors assess market performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper technical insights, aiding in more informed investment decisions, although the specific 200-day moving average value is not mentioned in the article.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, providing high liquidity in the market.
- Monitoring Inflows and Outflows: Weekly monitoring of changes in ETF units focuses on notable inflows (new units created) or outflows (old units destroyed), with these dynamics potentially impacting not only the ETF itself but also the individual stocks held within it.
See More
AbbVie's ABBV-295 Shows Significant Weight Loss in Phase 1 Study
- Significant Weight Loss: AbbVie's amylin analogue ABBV-295 demonstrated an average weight loss of 7.75% to 9.79% at week 12 with weekly dosing, indicating its potential to reshape the obesity treatment landscape.
- Flexible Dosing Regimen: With bi-weekly dosing followed by monthly dosing, average weight loss ranged from 7.86% to 9.73% at week 13, showcasing the drug's effectiveness across various administration schedules, enhancing its clinical applicability.
- Good Safety Profile: ABBV-295 was well tolerated across all doses (2mg to 14mg) with no serious adverse events reported, and the most common side effects were mild gastrointestinal issues, which increases its market acceptance.
- Mechanism Advantage: As an agonist activating amylin and calcitonin receptors, ABBV-295 offers a different mechanism of action compared to dominant GLP-1 drugs, potentially introducing new competitive dynamics in the obesity treatment market.
See More
AbbVie Reports Positive Results for ABBV-295 in Phase 1 Study
- Clinical Trial Results: AbbVie announced positive topline results from the Phase 1 study of ABBV-295, indicating good safety and tolerability, particularly highlighting significant weight loss effects.
- Weight Loss Efficacy: During the 12-13 week treatment period, the ABBV-295 group showed dose-dependent weight changes ranging from -7.75% to -9.79% at week 12, compared to only -0.26% in the placebo group, underscoring ABBV-295's potential in weight management.
- Participant Demographics: The study primarily enrolled male participants (88.3%) with a body mass index (BMI) below 30 kg/m2, providing insights into the target demographic for future marketing strategies.
- Dosing and Frequency: Various doses (2-14 mg) and titration frequencies were tested, with ABBV-295 demonstrating good tolerability across all levels, laying a solid foundation for its clinical application moving forward.
See More
Subtle Success of a Neglected Dividend ETF
Dividend Stocks and Investment Considerations: Investors are often drawn to dividend stocks based on their high yields, but it's essential to consider other factors such as the company's dividend growth history and potential challenges that may affect payouts.
Diversification through ETFs: Dividend-focused exchange-traded funds (ETFs) can provide a diversified approach to investing in dividend-paying companies, helping to balance risk and enhance stability in an investment portfolio.
Performance of DGRO ETF: The DGRO ETF, which tracks U.S. companies with a history of dividend growth, has shown strong performance, returning about 13% over the past year and offering a yield of nearly 2%.
Investment Recommendations: Analysts suggest considering a range of dividend stocks, including lesser-known firms, to ensure a well-rounded investment strategy, as they may provide stability and growth potential even in fluctuating market conditions.
See More
